Biosyngen Presents SUPER-T Cell Technology at ESMO 2024 for Enhanced CAR-T Therapy Safety and Efficacy
核心洞察
Biosyngen (搜索) presented its SUPER-T cell technology at ESMO 2024, featuring conditional activation and armor enhancement for safer, more effective CAR-T cell therapies.
The SUPER-T platform includes BTRP003L, activated in hypoxic tumor microenvironments, and BTRP011L, with enhanced efficacy and in vivo persistence at lower doses.
Preclinical toxicology studies of SUPER-T platform showed no significant adverse effects, demonstrating robust safety in initial assessments.
Biosyngen (搜索) presented its SUPER-T cell technology at the European Society for Medical Oncology (ESMO) Annual Congress in Barcelona, showcasing advancements in CAR-T cell therapy with enhanced safety and efficacy profiles. The innovative approach combines conditional activation and armor enhancement to target gastrointestinal tumors (搜索) more effectively while minimizing off-target toxicity.
Overcoming CAR-T Challenges in Solid Tumors
Gastrointestinal tumors (搜索) often exhibit elevated levels of tumor-associated antigens (TAAs), making them potential targets for immune cell therapies. However, the presence of TAAs in normal tissues poses a significant challenge for conventional CAR-T cells, leading to on-target off-tumor toxicity. This can result in damage to healthy organs, adverse clinical reactions, and limitations in dosage and efficacy.
To address these challenges, Biosyngen (搜索) developed the SUPER-T T cell safety optimization platform, which includes Conditional Activation CAR-T cell BTRP003L. This technology allows CAR-T cells to activate specifically in the hypoxic conditions typical of the tumor microenvironment (0.3% ~ 2.0% O2), while remaining inactive in normal tissues (3.4% ~ 6.8% O2). This conditional activation effectively regulates CAR-T cell activity and enhances antitumor capabilities.
"Conditional Activation + Armor Enhancement"
Further advancements led to the development of BTRP011L, which incorporates a TGFβRII (搜索) dominant-negative mutant, resulting in "Conditional Activation + Armor Enhancement." This CAR-T cell demonstrates improved efficacy and in vivo persistence at lower doses. Toxicology studies using the SUPER-T platform showed no weight loss or other adverse effects in mice injected with BTRP003L or BTRP011L, highlighting the platform's robust safety profile.
Biosyngen's Pipeline and Technology Platforms
Biosyngen (搜索) has secured ten clinical trial approvals in China and the U.S. for its fourth-generation oncology therapies. The company's lead product, BRG01, is currently in a pivotal Phase II clinical trial for solid tumors (搜索). Additionally, Phase I trials for BST02 and BRL03 are underway, with completion anticipated later this year.
Biosyngen (搜索)'s innovative technology platforms include:
- Identifier™ Platform: A drug discovery platform for identifying unique tumor antigens, antibodies, and TCRs, facilitating rapid screening and optimization.
- MSE-T™ Platform: A T-cell function enhancement platform that improves the ability of immune cells to recognize tumor-specific antigens and overcome the immunosuppressive tumor microenvironment.
- SUPER-T™ Platform: A T-cell safety optimization platform that enhances the safety of immunotherapy through conditional activation in the tumor microenvironment.